Clinical trials: Resectable Esophageal Squamous Cell Carcinoma
- Condition Resectable Esophageal Squamous Cell Carcinoma
- Funder type Industry (pharma, biotech, devices)
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, placebo-controlled Phase II/III clinical trial to evaluate the perioperative treatment with QL1706 in combination with neoadjuvant chemotherapy for locally advanced resectable esophageal…
- Trial name
- NCT06852456
- Testing
- Iparomlimab and Tuvonralimab (QL1706)Injection, Paclitaxel, Cisplatin
- Volunteers
- 30 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)
This is a randomized, controlled, multi-center phase II/III study. All patients are resectable locally advanced thoracic esophageal squamous cell carcinoma (ESCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT07263919
- Testing
- Cadonilimab (AK104), Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Akeso
Resectable Esophageal Squamous Cell Carcinoma
Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.
- Trial name
- RATIONALE-213 (NCT04974047)
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 8 sites in China
- Volunteers
- 70 people
- Sponsor
- BeiGene